Recent insights: mesenchymal stromal/stem cell therapy for acute respiratory distress syndrome

Horie, Shahd; Laffey, John G.

doi:10.12688/f1000research.8217.1

Cited by 23 publications

(21 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), attributable to the acute inflammation and dysfunction of alveolar–epithelial membrane, are usually characterized by pulmonary edema and manifested by severe respiratory dysfunction . A large number of experimental and clinical studies suggested that MSCs, due to their capacity to regenerate alveolar–epithelial barrier and to suppress detrimental immune response in the lungs, represent potentially new remedy in cell‐based therapy of ALI and ARDS …”

Section: Il‐1ra‐expressing Mscs As a New Therapeutic Agent In The Celmentioning

confidence: 99%

“…47,48 A large number of experimental and clinical studies suggested that MSCs, due to their capacity to regenerate alveolarepithelial barrier and to suppress detrimental immune response in the lungs, represent potentially new remedy in cell-based therapy of ALI and ARDS. [49][50][51] IL-1β has important pathogenic role in the development and progression of ALI and ARDS. 52 An increased concentration of IL-1β in lung airways is mainly responsible for the enhanced accumulation of neutrophils in the lungs following ALI.…”

Section: Il-1ra-expressing Mscs As a New Therapeutic Agent In The Cmentioning

confidence: 99%

See 1 more Smart Citation

The role of Interleukin 1 receptor antagonist in mesenchymal stem cell‐based tissue repair and regeneration

et al. 2019

View full text Add to dashboard Cite

Interleukin (IL)‐1 receptor antagonist (IL‐1Ra), a naturally occurring antagonist of IL‐1α/IL‐1β signaling pathways, has been attributed to the immunosuppressive effects of mesenchymal stem cells (MSCs). MSCs, in IL‐1Ra‐dependent manner, suppressed production of IL‐1β in dermal macrophages, induced their polarization in anti‐inflammatory M2 phenotype, attenuated antigen‐presenting properties of dendritic cells (DCs), and promoted expansion of immunosuppressive T regulatory cells in the skin, which resulted in enhanced repair of the nonhealing wounds. Reduced activation of inflammasome and suppressed production of IL‐1β in macrophages were mainly responsible for beneficial effects of MSC‐derived IL‐1Ra in alleviation of acute lung injury, dry eye syndrome, and corneal injury. Through the production of IL‐1Ra, MSCs reduced migration of DCs to the draining lymph nodes and attenuated generation of inflammatory Th1 and Th17 cells that resulted in alleviation of fulminant hepatitis and rheumatoid arthritis. MSCs, in IL‐1Ra‐dependent manner, reduced liver fibrosis by suppressing production of Type I collagen in hepatic stellate cells. IL‐1Ra was, at least partially, responsible for enhanced proliferation of hepatocytes and chondrocytes in MSC‐treated animals with partial hepatectomy and osteoarthritis. Despite of these beneficial effects, IL‐1Ra‐dependent inhibition of IL‐1α/IL‐1β‐signaling significantly increased risk of infections. Therefore, future experimental and clinical studies should delineate potential side effects of MSC‐derived IL‐1Ra before IL‐1Ra‐overexpressing MSCs could be used as a potentially new therapeutic agent for the treatment of acute and chronic inflammatory diseases.

show abstract

Section: Il‐1ra‐expressing Mscs As a New Therapeutic Agent In The Celmentioning

confidence: 99%

Section: Il-1ra-expressing Mscs As a New Therapeutic Agent In The Cmentioning

confidence: 99%

The role of Interleukin 1 receptor antagonist in mesenchymal stem cell‐based tissue repair and regeneration

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Recent studies have also shown that transplantation of MSCs from the bone marrow, umbilical cord (UC), menstrual blood (MB), and adipose tissue can attenuate lung injury and inflammatory responses [ 14 – 16 ]. Mechanistic studies revealed that MSCs can differentiate into lung tissue cells or exhibit paracrine functions [ 17 – 19 ]. For further application in ALI therapy, additional studies are needed to optimize several parameters of MSC therapy, such as cell sources, infusion routes, and doses.…”

Section: Introductionmentioning

confidence: 99%

Comparative Effects of Umbilical Cord- and Menstrual Blood-Derived MSCs in Repairing Acute Lung Injury

Ren

Zhang

Wang

et al. 2018

Stem Cells International

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) can effectively relieve acute lung injury (ALI) in several in vivo models. However, the underlying mechanisms and optimal sources of MSCs are unclear. In the present study, we investigated the effects of umbilical cord- (UC-) and menstrual blood- (MB-) derived MSCs on ALI. MSCs were transplanted into a lipopolysaccharide-induced ALI mouse model, and the therapeutic effects were determined by histological, cellular, and biochemical analyses. Our results showed that both UCMSC and MBMSC transplantation inhibited the inflammatory response and promoted lung tissue repair. UCMSC treatment resulted in reduced damage and inflammation in the lung tissue and enhanced protection of lung function. Furthermore, we found that UCMSCs secreted higher levels of anti-inflammatory cytokines (interleukin-10 and keratinocyte growth factor) in ALI-related conditions, which may be due to the greater therapeutic capacity of UCMSCs compared with MBMSCs. These findings suggest that MSCs protected the lipopolysaccharide-induced ALI model by regulating inflammation, most likely via paracrine factors. Moreover, MSCs derived from the UC may be a promising alternative for ALI treatment.

show abstract

“…Many studies have demonstrated that MSCs also release anti‐inflammatory cytokines that can dampen the severity of inflammation in ALI (Geiser et al, ; González et al, ; Ortiz et al, , ). These cells are potent modulators of the immune response and present a high degree of chemotaxis, based on proinflammatory cytokines, locating inflamed and neoplastic tissues (Arrieta, Ritz, & Silberstein, ; Horie & Laffey, ; Uccelli, Moretta, & Pistoia, ). MSCs also secrete paracrine factors that reduce the severity of ALI, including growth factors, factors that regulate barrier permeability, and anti‐inflammatory cytokines (Rojas et al, ; Wang et al, ).…”

Section: Introductionmentioning

confidence: 99%

Mesenchymal stem cells improves survival in LPS‐induced acute lung injury acting through inhibition of NETs formation

Pedrazza

Cunha

Luft

et al. 2017

Journal Cellular Physiology

View full text Add to dashboard Cite

Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are syndromes of acute hypoxemic respiratory failure resulting from a variety of direct and indirect injuries to the gas exchange parenchyma of the lungs. During the ALI, we have an increase release of proinflammatory cytokines and high reactive oxygen species (ROS) formation. These factors are responsible for the release and activation of neutrophil-derived proteases and the formation of neutrophil extracellular traps (NETs). The excessive increase in the release of NETs cause damage to lung tissue. Recent studies have studies involving the administration of mesenchymal stem cells (MSCs) for the treatment of experimental ALI has shown promising results. In this way, the objective of our study is to evaluate the ability of MSCs, in a lipopolysaccharide (LPS)-induced ALI model, to reduce inflammation, oxidative damage, and consequently decrease the release of NETs. Mice were submitted lung injury induced by intratracheal instillation of LPS and subsequently treated or not with MSCs. Treatment with MSCs was able to modulate pulmonary inflammation, decrease oxidative damage, and reduce the release of NETs. These benefits from treatment are evident when we observe a significant increase in the survival curve in the treated animals. Our results demonstrate that MSCs treatment is effective for the treatment of ALI. For the first time, it is described that MSCs can reduce the formation of NETs and an experimental model of ALI. This finding is directly related to these cells modulate the inflammatory response and oxidative damage in the course of the pathology.

show abstract

Recent insights: mesenchymal stromal/stem cell therapy for acute respiratory distress syndrome

Cited by 23 publications

References 39 publications

The role of Interleukin 1 receptor antagonist in mesenchymal stem cell‐based tissue repair and regeneration

The role of Interleukin 1 receptor antagonist in mesenchymal stem cell‐based tissue repair and regeneration

Comparative Effects of Umbilical Cord- and Menstrual Blood-Derived MSCs in Repairing Acute Lung Injury

Mesenchymal stem cells improves survival in LPS‐induced acute lung injury acting through inhibition of NETs formation

Contact Info

Product

Resources

About